Fully Human BCMA-Targeted Chimeric Antigen Receptor Autologous T-Cell therapy (Institute of Hematology & Blood Diseases Hospital)

N/A

Report date: 2026/02/15 20:00:16

Base Information

Drug NameFully Human BCMA-Targeted Chimeric Antigen Receptor Autologous T-Cell therapy (Institute of Hematology & Blood Diseases Hospital)

Drug Alias NameCT103d

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-BCMAT lymphocyte replacements

TargetsB-cell maturation protein

Therapy Area/IndicationsMultiple MyelomaLeukemia, Plasma Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesInstitute Of Hematology & Blood Diseases Hospital

China Registration ClassN/A

Develop Information

Active CompaniesInstitute Of Hematology & Blood Diseases Hospital

Inactive CompaniesN/A

Active IndicationsMultiple MyelomaLeukemia, Plasma Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A